Compare UNF & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNF | NUVB |
|---|---|---|
| Founded | 1936 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | UNF | NUVB |
|---|---|---|
| Price | $178.80 | $8.41 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $174.75 | $10.63 |
| AVG Volume (30 Days) | 208.0K | ★ 10.3M |
| Earning Date | 01-07-2026 | 11-03-2025 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 2.70 | N/A |
| EPS | ★ 7.98 | N/A |
| Revenue | ★ $2,432,352,000.00 | $26,748,000.00 |
| Revenue This Year | $3.19 | $609.55 |
| Revenue Next Year | $4.10 | $197.91 |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | 0.20 | ★ 1137.19 |
| 52 Week Low | $147.66 | $1.54 |
| 52 Week High | $243.70 | $8.95 |
| Indicator | UNF | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 68.86 |
| Support Level | $178.43 | $7.80 |
| Resistance Level | $186.04 | $8.95 |
| Average True Range (ATR) | 5.31 | 0.51 |
| MACD | 0.77 | -0.04 |
| Stochastic Oscillator | 74.04 | 77.09 |
UniFirst Corp provides workplace uniforms, protective clothing, and other workplace products and services to businesses in the United States, Canada, and Europe. The U.S. and Canadian Rental and Cleaning segment that accounts for the majority of the company engages in sales rents and sells clothing and non-garment items, and offers a cleaning service that delivers clean uniforms when it picks up dirty or contaminated ones. Manufacturing segment designs and manufactures uniforms and non-garment items. Specialty garments rental and cleaning segment provides specialty garments, non-garments, and cleaning services for nuclear and classroom applications. The First Aid segment provides safety supplies and pill packaging. The Corporate segment consists of various associated costs.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.